CriticalClass Ia antiarrhythmic with antimuscarinic activity×Non-selective beta blocker with class III antiarrhythmic activity
Updated · Methodology
Mechanism
Sotalol is a beta-blocker with class III antiarrhythmic properties. It prolongs the QT interval and can cause torsade de pointes, more often at higher doses, with a slow heart rate and with low potassium or magnesium (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Disopyramide, a class Ia antiarrhythmic, also prolongs the corrected QT interval (QTc). Torsade de pointes, ventricular tachycardia and ventricular fibrillation have occurred with it (disopyramide label, US Food and Drug Administration, FDA). Together the two drugs prolong refractoriness and raise the risk of ventricular arrhythmias, above all torsade de pointes (sotalol SmPC, AEMPS; sotalol FDA label). Both drugs also weaken heart muscle contraction: disopyramide through its negative inotropic effect (disopyramide FDA label) and sotalol through beta-blockade (sotalol SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes causes palpitations, dizziness and fainting. It may stop on its own or, in rare cases, progress to ventricular fibrillation. It usually starts soon after sotalol is started or its dose is increased (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Both drugs can lower blood pressure and cause new or worse heart failure with breathlessness and swelling. Sotalol also slows the heart rate and can cause atrioventricular block (sotalol and disopyramide labels, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The Spanish sotalol summary of product characteristics (SmPC) lists class Ia antiarrhythmics, disopyramide included, among the contraindicated QT-prolonging drugs (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The disopyramide SmPC contraindicates other antiarrhythmics, including beta-blockers and class III drugs, and drugs that can cause ventricular arrhythmias (disopyramide SmPC, AEMPS). According to the US sotalol label, stop class I and class III antiarrhythmics at least three half-lives before the first sotalol dose (sotalol label, US Food and Drug Administration, FDA). Start sotalol and increase its dose in a setting where heart rhythm can be monitored. Before that, record an electrocardiogram (ECG) with QT measurement and assess kidney function and electrolytes. Correct low potassium or magnesium before the first dose (sotalol SmPC, AEMPS). During disopyramide treatment, monitor potassium and correct it if needed (disopyramide SmPC, AEMPS). During sotalol treatment, if QRS or QT lengthens by 25% or more, PQ by 50% or more, or the corrected QT interval (QTc) exceeds 480 ms, reassess benefit and risk. In that case, seriously consider a lower dose or withdrawal (sotalol SmPC, AEMPS). Stop disopyramide if QT and QRS lengthen by more than 25% (disopyramide SmPC, AEMPS). Treat torsade de pointes caused by excess sotalol with direct-current (DC) cardioversion, transvenous pacing, adrenaline and/or magnesium sulfate (sotalol SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Betapace / Betapace AF (sotalol hydrochloride) tablets – prescribing information (2024)– FDA label, Legacy Pharma USA, DailyMed setid a6a7702f-36c9-45db-b640-453dc324baee, version 2, 12/2024, sections 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Sotalol (nº registro 89413), sección 4.5 (2024)– AEMPS, CIMA, nº registro 89413, revisión 03/2024, sección 4.5
- AEMPS: Ficha técnica: Disopiramida (nº registro 52549), sección 4.5 (2025)– AEMPS, CIMA, nº registro 52549 (Dicorynan), revisión 03/2025, secciones 4.3, 4.4 y 4.5
- FDA: Norpace (disopyramide) prescribing information (2026)– DailyMed setid e2aa1642-d262-4520-bc6a-9fd3ad795677, revisión 08/2026, Contraindications, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Sotapor (sotalol) (nº registro 62001), sección 4.3 (2022)– AEMPS, CIMA, nº registro 62001, revisión 11/2022, secciones 4.3, 4.4 y 4.5